MDL Supports Oracle Information Architecture for Life Sciences
MDL Information Systems, Inc. (MDL) has announced its support of Oracle(R) Corporation's Information Architecture for Life Sciences (IALS), Oracle's open technology and e-business platform that integrates both scientific and business applications for pharmaceutical and biotech companies. As the market leader in discovery informatics for the life sciences and chemistry, MDL will focus on optimizing its MDL(R) Discovery Framework with IALS.
'Oracle identified MDL as an early alliance for IALS because the vast majority of life science companies are already using MDL discovery informatics solutions,' said Jon Simmons, vice president of life sciences at Oracle Corp. 'This means that MDL is ideally positioned to assist Oracle in defining the IALS while also helping to promote an open, standards-based Oracle application platform within the life sciences community.'
Speaking at Life Sciences Day during Oracle AppsWorld in April, Lars Barfod, MDL's executive vice president and chief business officer, stressed the improvements in research productivity experienced by many customers who are successfully running MDL solutions on Oracle. Barfod expects MDL(R) Discovery Framework, the company's framework for integrating discovery content, applications, and technologies, to play an important role in IALS. By bringing together Oracle's technology platform for Life Sciences and business objects with MDL's industry-leading chemistry, biology, and ADME/Toxicology objects, Discovery Framework will let MDL customers create solutions that bridge the entire drug development cycle.
Barfod stated: 'This exciting life sciences partnership builds on MDL's very productive 15-year association with Oracle--a mutually beneficial business relationship highlighted by MDL's successful Oracle reselling program and the fact that our product strategy is naturally consistent with Oracle's direction for IALS.'
Other news from the department research and development
